ESC: PLATFORM Trial Results — FFRCT Can Reduce Need for Diagnostic Cath

LONDON, UK– According to results of the PLATFORM (Prospective LongitudinAl Trial of FFRCT: Outcome and Resource Impacts) trial, a test known as FFRCT  can obviate the need for invasive tests in up to 61% of patients who have chest pain and suspected coronary artery disease. FFRCT estimates fractional flow reserve (FFR) - a measure of blood flow and pressure in the coronary artery – using images from computed tomographic angiography (CTA).

ESC: ABSORB Japan Trial —BVS Compares Favourably Against Metal Stent

September 1, 2015, LONDON, England – A drug-eluting coronary stent, or “scaffold” made from bioresorbable material, showed similar efficacy and safety results compared to a metal stent in patients undergoing percutaneous coronary intervention (PCI), according to results of the ABSORB Japan study.

“These results support the feasibility of bioresorbable vascular scaffolds (BVS) to potentially improve the long-term outcomes of patients,” said principal investigator Takeshi Kimura MD, PhD, from Kyoto University Hospital, Kyoto, Japan.

ESC: No Benefit to Prolonging Bivalirudin After PCI (MATRIX Treatment Duration Trial)

September 1, 2015 — LONDON, UK – Extending treatment with the anticoagulant bivalirudin for at least four hours after completion of percutaneous coronary intervention (PCI) does not improve outcomes compared to stopping the treatment immediately after the procedure, according to results from the MATRIX Treatment Duration trial.

ESC: ABSORB STEMI TROFI II Trial — Absorbable Stents Prove Non-Inferior to Metal in STEMI Study

LONDON, UK – 01 September, 2015: A drug-eluting coronary stent made of absorbable material performed similarly to the gold-standard metal one in a non-inferiority trial among patients with the more serious type of heart attack known as ST-segment elevation myocardial infarction (STEMI), according to results of the ABSORB STEMI TROFI II trial.

ESC: BCM (Bioabsorbable Cardiac Matrix) Did Not Prevent Cardiac Remodelling (PRESERVATION I Trial)

An investigational material known Bioabsorbable Cardiac Matrix (BCM) that is injected through the coronary artery to prevent cardiac remodelling in heart attack patients had no significant effect compared to a saline placebo, according to results of the PRESERVATION I trial.

ESC: Respiratory Infection Associated With Increased Death After Acute MI

London, UK – 31 Aug 2015: Respiratory infection is associated with a four-fold increased risk of in-hospital cardiovascular mortality after acute myocardial infarction (AMI), according to research presented at ESC Congress today by Dr Catarina Quina-Rodrigues, a cardiologist at Hospital de Braga in Portugal.1 The findings highlight the importance of diagnostic alertness for respiratory infections in AMI patients so that therapeutic measures can be promptly taken.

ESC: BASKET-PROVE II Trial — Prasugrel Associated With Increased Major Bleeding in High-Risk Patients With Stable CAD

London, UK – 31 Aug 2015: Prasugrel-based dual antiplatelet therapy is associated with increased major bleeding after stent implantation for high-risk patients with stable coronary artery disease, according to a secondary analysis of the BASKET-PROVE II trial presented at ESC Congress for the first time today.1 Major bleedings were more pronounced in elderly and low-weight patients and raise concerns about the safety of prescriptions in these patients.

ESC: Results of OPTIDUAL Trial Suggest Extending Post-Stenting DAPT Beyond One Year

Extending clot-preventing dual antiplatelet therapy (DAPT) beyond the recommended 12 months after coronary stenting “should be considered” in patients at low risk for bleeding, investigators for the OPTIDUAL trial recommend.

Extending clot-preventing dual antiplatelet therapy (DAPT) beyond the recommended 12 months after coronary stenting “should be considered” in patients at low risk for bleeding, investigators for the OPTIDUAL trial recommend. Results of the trial were presented at a Hot Line session at ESC congress 2015 today.

LEADLESS II Trial Results Published in The New England Journal of Medicine Confirm the Positive Benefits of the Nanostim Leadless Pacemaker

Data from the LEADLESS II study also highlighted the St. Jude Medical Nanostim leadless pacemaker’s retrievability, projected longevity and the promising future of leadless pacing

Medtronic Study Detects Gene Associated with Sudden Cardiac Death

First-of-its-Kind Discovery Furthers Understanding of Role of Genetics in Sudden Cardiac Death, May Help Identify Patients at Increased Risk

DUBLIN and LONDON - August 31, 2015 - Medtronic plc (NYSE: MDT) today announced first-of-its-kind findings from two independent studies that have identified a gene associated with life-threatening abnormal heart rhythms. The study results were presented in a hotline session at the 2015 European Society of Cardiology (ESC) Congress in London.


Back to top